About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NI... [Read more]
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Sep 24, 1944
Employees 152,700
Stock Exchange NYSE
Ticker Symbol JNJ
Full Company Profile
Financial Performance
In 2022, JNJ's revenue was $94.94 billion, an increase of 1.25% compared to the previous year's $93.78 billion. Earnings were $17.94 billion, a decrease of -14.07%.
Financial Statements
Analyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $166.5, which is an increase of 6.36% from the latest price.
Price Target
$166.5
(6.36% upside)
Analyst Consensus: Buy
Stock Forecasts
News
Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada
Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching the biosimilar of the pharmaceutical giant's blockbuster psoriasis drug Stelara in Japan, Canada and...
Other symbols: ALVO
1 day ago - Reuters
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, ...
2 days ago - Business Wire
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL. Joe Wolk, ...
4 days ago - Business Wire
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma,...
Other symbols: AMAM
6 days ago - Business Wire
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.
Other symbols: BMYMRK
8 days ago - Market Watch
US Senate Democrats grill pharma CEOs on drug prices
U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.
Other symbols: BMYMRK
8 days ago - Reuters
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For
Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.
Other symbols: BMYMRK
8 days ago - Forbes
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.
Other symbols: BMYMRK
8 days ago - CNBC
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.
Other symbols: BMYMRK
9 days ago - Market Watch
J&J Accused of Mismanaging Its Employees' Drug Benefits
The novel lawsuit by a J&J worker alleges employees overpaid for some drugs.
11 days ago - WSJ
J&J's immune disorder drug succeeds in studies
Johnson & Johnson's experimental drug to treat two autoimmune disorders met the main goals in mid-stage and late-stage trials, the company said on Monday.
11 days ago - Reuters
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5th, at the JW Marriott Orlan...
14 days ago - Business Wire
Dow Stocks To Trade In February
For this month, the cycle/relative strength concept is applied. First, the Dow Jones 30 stocks are ranked from the best performer to the worst by calculating the expected return in that month.
Other symbols: CATCRMDOWIBMJPMMMMMSFT
15 days ago - Forbes
4 med tech stocks with improving prognosis for 2024
Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate,...
Other symbols: ABTISRGSYK
16 days ago - MarketBeat
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.
Other symbols: BMYMRK
17 days ago - CNBC
Pharma industry to get US government price cut proposals by Thursday
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's...
Other symbols: ABBVAMGNBMYMRKPFE
18 days ago - Reuters
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
Other symbols: MRKBMY
19 days ago - CNBC
AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
20 days ago - PRNewsWire
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.
Other symbols: MRK
21 days ago - CNBC
JNJ, LLY: Health Care Earnings To Watch
Eli Lilly (LLY) is up over 80% year-over-year. Lee Brown discusses health care stocks.
Other symbols: LLY
21 days ago - Schwab Network
Washington state reaches nearly $150 million settlement with Johnson & Johnson over opioid crisis
OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its...
23 days ago - Market Watch
J&J Can't Promise Wall Street No More Tears
Some investors struggle with owning the shares because of uncertainty over ongoing baby powder lawsuits.
23 days ago - WSJ
J&J Sees Surge in MedTech Sales Post-Kenvue Split
Six months after parting ways with its consumer health unit,Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding qu...
24 days ago - PYMNTS
Drug Pipeline Is Well Positioned for 2024, Says J&J CFO
Joseph Wolk, Johnson & Johnson Chief Financial Officer, says the drug pipeline is well positioned for this year. He also comments on their earnings and the use of artificial intelligence in medicine a...
24 days ago - Bloomberg Markets and Finance
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.
24 days ago - CNBC
